MGRM Nasdaq· Monogram Orthopaedics Inc
FundamentalsNews digest Peer analysis
MGRM Nasdaq· Monogram Orthopaedics Inc
Earnings report Q3 2023

MGRM Reports Strong Revenue Growth in Latest Quarter

Segments of revenue

In the latest quarter, Monogram Orthopaedics Inc. (MGRM) reported total product revenue of $0, reflecting a significant increase compared to the same period last year when there was no product revenue generated.


The significant increase in product revenue can be attributed to the successful completion of the Common Stock Offering, which helped drive the company's financial performance. The increase in marketing and advertising spend during the nine months ended September 30, 2023, compared to the same period in 2022, also contributed to the growth in revenue.


Despite the strong revenue growth, MGRM faced challenges in managing its operating expenses. General and Administrative expenses increased significantly by 135% during the quarter and 109% during the nine months ended September 30, 2023, compared to the same periods in 2022. This increase was primarily driven by higher compensation expenses, insurance and regulatory compliance expenses, facilities expenses, and consulting and professional fees.


It is worth noting that MGRM experienced a loss from operations of $3.76 million in the latest quarter, compared to a loss of $1.81 million in the same period last year. However, the company managed to generate other income of $2.76 million, primarily due to a change in the fair value of warrant liability. This resulted in a net loss of $0.99 million for the quarter.


Despite the challenges in managing operating expenses, MGRM reported strong revenue growth in the latest quarter, primarily driven by the success of the Common Stock Offering and increased marketing and advertising spend. The company's ability to generate other income helped offset the loss from operations, resulting in a net loss for the quarter. Overall, MGRM's financial performance reflects positive momentum, but careful cost management will be crucial for future profitability.

Source documents

Form 10-Q  filed on Nov 08, 2023
34 pages scanned

Reference data

Company financials Q3 revenue 0
Analyst estimates Q3 EPS missed by NaN%
Sign up to Fey

Get in-depth analysis on thousands of stocks for just $30/month. Cancel anytime.